NCT00355446已完成4 期
Bioavailabilty of Bimatoprost Ophthalmic Solution in Human Aqueous.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 4
- 主要终点
- Bimatoprost free acid in human aqueous
研究概览
简要总结
The purpose of this study is to assay human aqueous for bimatoprost and the presence of any metabolites, especially prostaglandin analogs. Hypothesis:Bimatoprost is not metabolized to a prostaglandin F-2-alpha analog in human eyes
- Bimatoprost levels in human aqueous peak approximately three hours post dosing
详细描述
The purpose of this study is to assay human aqueous for bimatoprost and the presence of any metabolites, especially prostaglandin analogs
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects must:
- •Be willing and able to provide written Informed Consent.
- •Be able and willing to follow instructions and likely to complete the entire course of the study.
- •Be male or female of any race at least 18 years of age.
- •Have visually significant cataract for which they have elected to undergo cataract surgery..
排除标准
- •No subject may:
- •1. Have any contraindication to use of a prostaglandin analog or prostamide derivative.
- •3. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). Patients with mild chronic blepharitis, age-related macular degeneration, background diabetic retinopathy may be enrolled at the discretion of the investigator.
- •4. Have laser or any other intraocular surgery within the past three months.
- •Require use of ocular medications (including glaucoma medications), except intermittent use of artificial tears. Patients may not have a history of ever having used a prostaglandin analog topically.
- •6. Have known allergy or sensitivity to the study medications or their components
- •Have corneal abnormalities that would interfere with the ability to obtain an adequate sample safely or have a shallow anterior which would make obtaining an aqueous sample difficult at the time of surgery in the opinion of the investigator.
- •8. Be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study.
- •9. Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception (a woman is considered of childbearing potential unless she is postmenopausal, has had a uterus and/or both ovaries removed, or has had a bilateral tubal ligation).
- •10. Have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study.
结局指标
主要结局
Bimatoprost free acid in human aqueous
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash ProminenceEyelash HypotrichosisNCT01064882Allergan104
已完成
3 期
Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash ProminenceEyelashesNCT00693420Allergan278
已完成
2 期
A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00538304Allergan222
已完成
4 期
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash HypotrichosisHypotrichosisNCT00958035Allergan89
已完成
2 期
Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00300443Allergan561